NASDAQ:CMND Clearmind Medicine (CMND) Stock Price, News & Analysis $3.07 -0.07 (-2.23%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$3.06 -0.01 (-0.26%) As of 06/18/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Clearmind Medicine Stock (NASDAQ:CMND) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Clearmind Medicine alerts:Sign Up Key Stats Today's Range$2.94▼$3.4450-Day Range$2.26▼$14.3052-Week Range$2.10▼$524.00Volume1.28 million shsAverage Volume4.64 million shsMarket Capitalization$3.13 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Clearmind Medicine, Inc. is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia. Clearmind’s pipeline includes multiple preclinical and early clinical candidates. Among these is an iboga alkaloid analog designed to treat neuropathic pain and opioid use disorder, as well as a series of next-generation psychoplastogens for major depressive disorder and post-traumatic stress disorder. The company’s research programs also explore applications in mild traumatic brain injury and Alzheimer’s-type dementias, with the goal of delivering therapies that restore neural circuitry and improve cognitive function. Headquartered in North America, Clearmind Medicine operates research facilities and partnerships across Canada and the United States. The company collaborates with academic institutions and contract research organizations to advance its drug candidates through toxicology studies and human trials. By combining proprietary medicinal chemistry with established preclinical models, Clearmind seeks to streamline development timelines and establish differentiated therapeutic profiles. Clearmind’s leadership team comprises professionals with deep expertise in neuroscience, clinical development and regulatory affairs. The company’s board and scientific advisors include experts in psychopharmacology, neurology and drug development strategy, reflecting a commitment to rigorous science and commercial execution. As a Nasdaq-listed entity, Clearmind Medicine continues to expand its research collaborations and augment its pipeline in pursuit of new treatments for underserved neurological and psychiatric indications.AI Generated. May Contain Errors. Read More Clearmind Medicine Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreCMND MarketRank™: Clearmind Medicine scored higher than 60% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Clearmind Medicine. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Clearmind Medicine is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Clearmind Medicine is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioClearmind Medicine has a P/B Ratio of 0.27. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.97% of the float of Clearmind Medicine has been sold short.Short Interest Ratio / Days to CoverClearmind Medicine has a short interest ratio ("days to cover") of 0.01, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Clearmind Medicine has recently decreased by 80.27%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldClearmind Medicine does not currently pay a dividend.Dividend GrowthClearmind Medicine does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment0.50 News SentimentClearmind Medicine has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Clearmind Medicine this week, compared to 5 articles on an average week.Search Interest6 people have searched for CMND on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows1 people have added Clearmind Medicine to their MarketBeat watchlist in the last 30 days. Company Ownership3.6 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $205,925.00 in company stock, which represents 6.5761% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Clearmind Medicine insiders have bought 174.61% more of their company's stock than they have sold. Specifically, they have bought $323,858.00 in company stock and sold $117,933.00 in company stock.Percentage Held by Institutions96.05% of the stock of Clearmind Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Clearmind Medicine's insider trading history. Receive CMND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clearmind Medicine and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CMND Stock News HeadlinesClearmind Medicine (NASDAQ:CMND) Major Shareholder Sells $10,567.56 in StockJune 18 at 8:44 AM | insidertrades.comClearmind Medicine Granted U.S. Patent for Binge Behavior RegulatorsJune 18 at 7:55 AM | globenewswire.comTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now. | Altimetry (Ad)Clearmind Medicine Inc. Successfully Completes Dosing in Phase I/II Clinical Trial for CMND-100 to Treat Alcohol Use DisorderJune 16 at 7:50 AM | quiverquant.comQClearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical TrialJune 16 at 7:32 AM | globenewswire.comClearmind Medicine (NASDAQ:CMND) Major Shareholder Sells $27,022.92 in StockJune 13, 2026 | insidertrades.comClearmind Medicine jumps 24.1% as traders react to fresh CMND-100 updates and upcoming June 10 webinarJune 5, 2026 | quiverquant.comQClearmind Medicine Inc. to Host Live Webinar on MEAI and Alcohol Use Disorder with Yale and Johns Hopkins on June 10, 2026June 5, 2026 | quiverquant.comQSee More Headlines CMND Stock Analysis - Frequently Asked Questions How have CMND shares performed this year? Clearmind Medicine's stock was trading at $18.10 on January 1st, 2026. Since then, CMND stock has decreased by 83.0% and is now trading at $3.07. How were Clearmind Medicine's earnings last quarter? Clearmind Medicine Inc. (NASDAQ:CMND) issued its quarterly earnings results on Monday, June, 15th. The company reported ($6.78) earnings per share (EPS) for the quarter. When did Clearmind Medicine's stock split? Clearmind Medicine's stock reverse split before market open on Tuesday, November 28th 2023.The 1-30 reverse split was announced on Tuesday, November 28th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, November 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Clearmind Medicine IPO? Clearmind Medicine (CMND) raised $9 million in an initial public offering (IPO) on Tuesday, November 15th 2022. The company issued 1,300,000 shares at a price of $6.00-$8.00 per share. Aegis Capital Corp. served as the underwriter for the IPO. How do I buy shares of Clearmind Medicine? Shares of CMND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Clearmind Medicine own? Based on aggregate information from My MarketBeat watchlists, some other companies that Clearmind Medicine investors own include NVIDIA (NVDA), Broadcom (AVGO), Adobe (ADBE), Arista Networks (ANET), Meta Platforms (META), AppLovin (APP) and e.l.f. Beauty (ELF). Company Calendar Last Earnings6/15/2026Today6/18/2026Fiscal Year End10/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3w+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 For the last 3 weeks, CMND's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CMND CIK1892500 Webwww.clearmindmedicine.com Phone604-260-1566FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)($197.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.86 million Net MarginsN/A Pretax MarginN/A Return on Equity-143.79% Return on Assets-88.51% Debt Debt-to-Equity RatioN/A Current Ratio4.79 Quick Ratio3.79 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$11.28 per share Price / Book0.27Miscellaneous Outstanding Shares1,020,000Free FloatN/AMarket Cap$3.13 million OptionableNot Optionable Beta0.64 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:CMND) was last updated on 6/19/2026 by MarketBeat.com Staff. From Our PartnersTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredThe roadshow starts Monday. This stock isn't ready.The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...Behind the Markets | SponsoredA huge SpaceX error just led one stock to 3X move!SPCE surged roughly 300% in a single week after investors hunting SpaceX exposure piled into the wrong ticker....InvestPub | SponsoredSpaceX is chump change compared to Elon’s $20T ‘iPhone’Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredPorter flew 3,300 miles to investigate this systemPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clearmind Medicine Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clearmind Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
